Go to Top

We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer.

About Us

About Us

Dual mechanism selective CYP17 lyase and androgen receptor (AR) inhibitors have high commercial potential for the treatment of  breast cancer and CRPC as well as other cancers that utilize sex steroids as growth factors (e.g., ovarian, bladder, hepatocellular, and lung). CYP17 lyase and AR inhibitors also have potential for the treatment of non-oncologic syndromes that are due to excessive androgen production such as endometriosis, polycystic ovary syndrome, congenital adrenal hyperplasia, and precocious puberty.

Intellectual Property

Our lead molecule, seviteronel (formerly VT-464), a selective CYP17 lyase and AR inhibitor, and multiple classes of chemically-distinct CYP17 lyase inhibitors are covered by composition of matter and use patents through at least 2031. This intellectual property is wholly owned by Innocrin, with no financial obligations due to third parties.